Show simple item record

dc.contributor.authorKoff, Wayne C
dc.contributor.authorSchenkelberg, Theodore
dc.contributor.authorWilliams, Tere
dc.contributor.authorBaric, Ralph S
dc.contributor.authorMcDermott, Adrian
dc.contributor.authorCameron, Cheryl M
dc.contributor.authorCameron, Mark J
dc.contributor.authorFriemann, Matthew B
dc.contributor.authorNeumann, Gabriele
dc.contributor.authorKawaoka, Yoshihiro
dc.contributor.authorKelvin, Alyson A
dc.contributor.authorRoss, Ted M
dc.contributor.authorSchultz-Cherry, Stacey
dc.contributor.authorMastro, Timothy D
dc.contributor.authorPriddy, Frances H
dc.contributor.authorMoore, Kristine A
dc.contributor.authorOstrowsky, Julia T
dc.contributor.authorOsterholm, Michael T
dc.contributor.authorGoudsmit, Jaap
dc.date.accessioned2021-03-05T17:58:58Z
dc.date.available2021-03-05T17:58:58Z
dc.date.issued2021-02-03
dc.identifier.urihttp://hdl.handle.net/10713/14848
dc.description.abstractDevelopment of safe and effective COVID-19 vaccines is a global priority and the best hope for ending the COVID-19 pandemic. Remarkably, in less than 1 year, vaccines have been developed and shown to be efficacious and are already being deployed worldwide. Yet, many challenges remain. Immune senescence and comorbidities in aging populations and immune dysregulation in populations living in low-resource settings may impede vaccine effectiveness. Distribution of vaccines among these populations where vaccine access is historically low remains challenging. In this Review, we address these challenges and provide strategies for ensuring that vaccines are developed and deployed for those most vulnerable. Copyright © 2021 The Authors.en_US
dc.description.urihttps://doi.org/10.1126/scitranslmed.abd1525en_US
dc.language.isoenen_US
dc.publisherAmerican Association for the Advancement of Scienceen_US
dc.relation.ispartofScience Translational Medicineen_US
dc.rightsCopyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.en_US
dc.subject.meshCOVID-19 Vaccines--supply & distributionen_US
dc.subject.meshVulnerable Populationsen_US
dc.titleDevelopment and deployment of COVID-19 vaccines for those most vulnerableen_US
dc.typeArticleen_US
dc.identifier.doi10.1126/scitranslmed.abd1525
dc.identifier.pmid33536277
dc.source.volume13
dc.source.issue579
dc.source.countryUnited Kingdom
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record